Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab for PLA2R antibody kinetics in primary membranous nephropathy
NL-OMON59238Phase 2Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in idiopathic membranous glomerulonephritis (IMG), sponsored by Radboud University Medical Center. Primary endpoint: Disappearance rate (half-life) of anti-PLA2R antibodies. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
obinutuzumab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on NL-OMON59238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59238.